ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

AstraZeneca has produced some fresh data to ... Physicians then monitored circulating tumor DNA to spot ESR1 mutations. If a mutation was found before disease progression, patients switched ...

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of initial treatment, potentially opening a novel step in patient care.

AstraZeneca has unveiled positive trial results for a breast cancer drug that can stop mutating tumours before they start to grow, hoping it will be one of a portfolio of medicines that will propel it ...

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...

Breast cancer patients whose tumors have spread to other parts of their bodies live from scan to scan. Is their treatment working? Or will they learn their cancer is growing again? But a new study ...

The results, published in Nature Communications, point to what could be the most effective treatment to date for early-stage ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...